Myomo Inc. Chief Medical Officer Harry Kovelman sold 17,500 ordinary shares in an open-market transaction on August 20, 2026, for a total of $30,329 at a weighted average price of $1.7331 per share. The shares were priced between $1.72 and $1.75 during the disposal, according to a regulatory filing.
The disposal follows a 164% gain in Myomo's stock over the prior six months, with shares trading near the 52-week high of $1.89. Kovelman retains direct ownership of 105,733 ordinary shares of the company following the transaction.
The filing was submitted as an amendment to a prior report, correcting the number of shares sold and adjusting the reported beneficial ownership. Myomo reported a 21% year-over-year increase in revenue to $11.7 million for the second quarter, exceeding Wall Street expectations of $10.29 million. The company also narrowed its net loss to $0.09 per share, better than the anticipated $0.10 loss, while gross margins improved significantly.
Myomo attributed the results to record quarterly orders of 255 units of its MyoPro device. The company raised its full-year sales outlook following the quarterly performance.
